xfs
[Top] [All Lists]

Probable Upcoming Sales of Nuvilex, Inc. (NVLX) Cancer Treatments Render

To: xfs@xxxxxxxxxxx
Subject: Probable Upcoming Sales of Nuvilex, Inc. (NVLX) Cancer Treatments Render Investment in Technology Valuable
From: "Investor's Daily Update" <hxrhps@xxxxxxxxxxxxx>
Date: Wed, 27 Mar 2013 08:12:36 -0600
Delivered-to: xfs@xxxxxxxxxxx
Dkim-signature: v=1; a=rsa-sha1; c=relaxed/relaxed; s=mg11; d=dalledaw.info; h=To:Subject:Message-ID:Date:From:Reply-To:MIME-Version:List-Unsubscribe:Content-Type:Content-Transfer-Encoding; i=hxrhps@xxxxxxxxxxxxx; bh=RF0G7q7eOXr0yTt+7cW6/AAgHCg=; b=JDsnzh+d+QiI/OwvOID9gQ0Cr4Pwb7gg/+Q0yJizVnOmbz0BodLEit8p+AsT7Ekqikm0lQK058Lp yegs0sykKAja6qsr6XTsZhESyrePFF3aDv8ui2ASFVc0FbqV44WqvnOdnX19zi6TU1njfVOyRvho R77oNDK8Gnyu8AUWF4E=
Domainkey-signature: a=rsa-sha1; c=nofws; q=dns; s=mg11; d=dalledaw.info; b=iPR6siAx7vawRu/G/3kHmxTASS7DmzE5v+oNt/UJukfCEXyPG03idh4uSSoKBWvMkzTHQ+Kp87BU QNYzYn2M413gwnjywZK2idf2xP3IwAhTxNv/2wqS5ZyZRyFSFn87uhl3NHqZKl0sF65MMBedLnjH He9xH0WFT73NiJB1m5k=;
List-unsubscribe: <http://dalledaw.info/unsubscribe.php?M=29060591&C=f4ddb30d6c4e320f9aafb7af995cb9f5&L=71&N=166>
Reply-to: hxrhps@xxxxxxxxxxxxx

Budding Upcoming Sales of Nuvilex, Inc. (NVLX) Cancer Treatments Render Investment in Technology Worth It

As Nuvilex, Inc. (OTCQB: NVLX) persistently primes for its Phase III pancreatic cancer trials, the nearly $30-million it has invested in its exclusive and one-of-a-kind living cell encapsulation or “Cell-in-a-Box” technology could be assets well invested given the return in annual sales that cancer medications beget in the marketplace.

The first type the company is choosing to challenge is advanced pancreatic cancer – a market that Eli Lilly’s medication Gemzar has cornered and yields about $1.4-billion yearly.

Nuvilex has about $25-million invested in two independent Phase II clinical trials in patients with advanced, inoperable pancreatic cancer using the combination of the broadly-used anticancer medication, ifosfamide, and encapsulated cells capable of changing the ifosfamide, into its “cancer-killing” form as well as for preclinical studies researching the potential use of the cell encapsulation technology in the advancement of treatments for other cancers and other diseases. Also, the company has earmarked almost another $2-million into advancing the development of the “Cell-in-a-Box” technology.

This is a pretty large price tag for such a small biotech, but with the outcomes the company has seen in its two clinical trials, the future looks very hopeful. In those trials, the outcomes are outperforming the current gold standard, the aforementioned Eli Lilly’s medicine Gemzar.

Cancer medications are big business, and those medications are even bigger business when they are successful, and when they prolong lives, and so far, Nuvilex’s cell encapsulation technology has shown it does work and it does prolong lives.

A glance at the significant outcomes in those two trials demonstrate that with twenty-seven patients included, a substantial response was seen in that the use of the living cell encapsulation-ifosfamide grouping helped patients to a better outcome than that previously reported with standard single-medication (Gemzar) therapy.

Outcomes from these trials included; average survival time and one-year survival rate were almost doubled as equated to historical data for Gemzar. The gravity of ifosfamide's side effects was lessened because only one-third of its normal dose was used. No harm to tissues adjacent to the capsules was seen. Cells inside the capsules were guarded from harm by the patients’ immune systems. Cells inside the capsules were alive and functioning – even after more than two years.

And, this is only the treatment for advanced pancreatic cancer which is as harsh a disease as you can find – what about using this technology as a remedy for other types of cancer? Nuvilex’s “Cell-in-a-Box” technology could make its mark enhancing on the industry norm in one kind of cancer after the other, and when you start to consider the billions being generated each year in those medicines, that undoubtedly makes the technology well worth the investment to date.

Unsubscribe | Disclaimer

10200 Forest Green Blvd, Suite 112, Louisville, Kent. 40223 USA

<Prev in Thread] Current Thread [Next in Thread>
  • Probable Upcoming Sales of Nuvilex, Inc. (NVLX) Cancer Treatments Render Investment in Technology Valuable, Investor's Daily Update <=